CEBPA gene mutational status: a complete screening using high-resolution melt curve analysis
Jazyk angličtina Země Nový Zéland Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
19650672
DOI
10.2165/01250444-200913030-00004
PII: 4
Knihovny.cz E-zdroje
- MeSH
- denaturace nukleových kyselin MeSH
- lidé MeSH
- molekulární sekvence - údaje MeSH
- mutace genetika MeSH
- mutační analýza DNA metody MeSH
- protein alfa vázající zesilovač transkripce CCAAT genetika MeSH
- sekvence nukleotidů MeSH
- tranzitní teplota MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- protein alfa vázající zesilovač transkripce CCAAT MeSH
In recent years, several independent prognostic factors in cytogenetically normal acute myeloid leukemia (CN-AML) have been reported. Mutations or the expression levels of certain genes have been often used as molecular markers for prediction of a patient's outcome or for evaluation of treatment outcome. One of them, the gene encoding CCAAT/enhanced binding protein alpha (CEBPA), plays an important role in myeloid differentiation and, when mutated, confers a favorable prognosis for patients with CN-AML. Complete mutation screening of the CEBPA gene is therefore beneficial and requires fast, precise, and sensitive diagnostic tools. Thus, for routine diagnostics, we developed a screening method using high-resolution melt curve analysis prior to direct sequencing, where only positive samples (according to reference) are further sequenced. With this approach, all positive and negative patients were successfully distinguished, and the results obtained were in absolute concordance with the direct sequence analysis.
Zobrazit více v PubMed
Cancer Cell. 2008 Apr;13(4):289-91 PubMed
J Hematol Oncol. 2008 Jul 29;1:10 PubMed
Br J Haematol. 2003 Nov;123(3):413-9 PubMed
Leukemia. 2005 Mar;19(3):329-34 PubMed
Blood. 2002 Feb 15;99(4):1332-40 PubMed
Haematologica. 2008 Oct;93(10):1560-4 PubMed
Pharmacogenomics. 2007 Jun;8(6):597-608 PubMed
Blood. 2002 Oct 15;100(8):2717-23 PubMed
Leukemia. 2008 May;22(5):915-31 PubMed
Folia Biol (Praha). 2007;53(3):97-108 PubMed
Leuk Res. 2008 Aug;32(8):1236-43 PubMed
Nat Med. 2001 Apr;7(4):444-51 PubMed
Annu Rev Genomics Hum Genet. 2002;3:179-98 PubMed
Eur J Haematol. 2008 Oct;81(4):273-80 PubMed
J Mol Diagn. 2004 Aug;6(3):211-6 PubMed
Hematol J. 2003;4(1):31-40 PubMed
J Clin Oncol. 2004 Feb 15;22(4):582-4 PubMed
BMC Cancer. 2007 Aug 31;7:168 PubMed
Nat Genet. 2002 Jan;30(1):48-58 PubMed
Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74 PubMed
Br J Haematol. 2006 Apr;133(1):103-5 PubMed
Nat Genet. 2001 Mar;27(3):263-70 PubMed
Br J Haematol. 2008 Oct;143(2):230-9 PubMed
Leukemia. 2006 Oct;20(10):1899-903 PubMed
